Biotech entity

Citadel Advisors LLC

Company

Weiss Ratings is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Coverage clusters in pharma, which accounts for 2 of those 3, with the remainder spread across 1 other category. Each carries 2 original sources on average.

Last mentioned: Aug 13, 2026

RSS updates
Share

Entity pulse

Recent coverage · Citadel Advisors LLC

↑
3 stories
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Citadel Advisors LLC

Weiss Ratings is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Coverage clusters in pharma, which accounts for 2 of those 3, with the remainder spread across 1 other category. Each carries 2 original sources on average. Citadel Advisors LLC appears in 3 tracked Biotech stories published from August 12, 2026 through August 13, 2026.

Stories tracked
3
Sources per story
2

Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Citadel Advisors LLC. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Shares drop 1.8%

    APYX traded as low as $4.34 and last at $4.38 on volume of 43,859 shares, 60% below average.

  2. Weiss Ratings reiterates sell

    Weiss Ratings reissued a sell (d-) rating on Apyx Medical shares.

  3. Q1 earnings beat

    Apyx Medical reported Q1 EPS of -$0.05 vs -$0.11 expected and revenue of $12.49M vs $10.53M expected.

  4. Wall Street Zen downgrades APYX

    Wall Street Zen lowered Apyx Medical from a buy rating to a hold rating.

Stories mentioning Citadel Advisors LLC 3

Funding Neutral

Apyx Medical EPS Beats by $0.06, Stock Still Slides 1.8% to $4.38

For biotech and pharma investors, Apyx Medical's Q1 loss of $0.05 per share beat consensus by $0.06, but the stock fell 1.8% to $4.38 on low volume. Mixed analyst ratings and a $6.50 consensus target raise questions about whether the small-cap device maker can convert clinical and operational beats into stock appreciation. Institutional repositioning signals ongoing evaluation of the company's commercial ramp.

2 sources

Source: dailypolitical.com · tickerreport.com

Citadel Advisors LLC is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.